Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms

Loghavi, Sanam; Kanagal-Shamanna, Rashmi; Khoury, Joseph D.; Medeiros, L. Jeffrey; Naresh, Kikkeri N.; Nejati, Reza; Patnaik, Mrinal M.

doi:10.1016/j.modpat.2023.100397

Cited by 6 publications

(1 citation statement)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Myeloproliferative neoplasms (MPNs) are hematological disorders affecting myeloid stem cells. According to the 5th edition of the WHO classification of myeloid neoplasms, MPN can be classified as Philadelphia (Ph) chromosome positive-chronic myeloid leukemia (CML), and Ph-negative polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia (CEL), juvenile myelomonocytic leukemia (JMML), and MPN unclassifiable (MPN-U) [1,2]. However, the main Ph-negative MPNs; PV, ET, and PMF, are the focus of this review.…”

Section: Introductionmentioning

confidence: 99%

Mutational Analysis of Driver and Non-driver Mutations of Philadelphia Chromosome-negative Myeloproliferative Neoplasms; Diagnosis and Recent Advances in Treatment

Afolabi,

Riwaz,

Weerasena

et al. 2024

WJCOR

View full text Add to dashboard Cite

Myeloproliferative neoplasms (MPNs) are hematological disorders affecting myeloid stem cells. They are classified as Philadelphia (Ph) chromosome positive-chronic myeloid leukemia, and Ph-negative polycythemia vera, essential thrombocythemia, primary myelofibrosis, chronic neutrophilic leukemia, chronic eosinophilic leukemia, juvenile myelomonocytic leukemia, and MPN unclassifiable. This review is mainly focused on the Ph-negative MPNs namely, PV, ET, and PMF. These affect both males and females with a slight male predominance, with patients mainly presenting in the seventh decade. Patients often present with thrombotic events resulting in complications that lower survival rates. The major driver mutations that have been identified in MPNs are JAK2 Exon 14, JAK2 Exon 12, MPL Exon 10, and CALR Exon 9. The importance of these driver mutations gives due recognition to their inclusion into the 2022 diagnostic criteria of the MPN WHO Classification. However, other non-driver mutations have also been reported, especially in triple-negative cases. These mutations lead to downstream constitutive activation of the JAK/STAT signaling pathway, as well as the MAPK, and PI3K/Akt pathways. Insights into the molecular pathogenesis of MPN and its association with JAK2, CALR, and MPL mutations have identified JAK2 as a rational therapeutic target. Thus, as an approach to MPN therapy, JAK2 inhibitors, such as ruxolitinib, have been shown to effectively inhibit JAK2, and are currently in clinical trials in combination with other drug classes. This review comprehensively examines the molecular markers of the main Ph-negative MPNs, as well as diagnosis and treatment options.

show abstract

Section: Introductionmentioning

confidence: 99%